← Eichor
Study identifier: NCT07359183 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment)

Condition: Food Allergies · Peanut Allergies · Egg Allergy  ·  Sponsor: Murdoch Childrens Research Institute

PhaseN/A
Planned participants147
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to learn about the long-term outcomes of children and young people who underwent an 18-month course of oral immunotherapy (OIT) treatment for peanut, egg or milk allergy. It aims to: • Compare long-term changes in health-related quality of life (HRQL) at 5-15 years after stopping OIT in participants who achieved remission and those who did not. Participants will attend a single follow-up visit for: * A blood test * Skin prick test (SPT) * Allergy questionnaires

This description comes directly from the study's public registry record.

Talk to the study team

Adriana Chebar Lozinsky Rolnik  ·  61399366435  ·  lpem.study@mcri.edu.au

Amanda Burgess  ·  +61383416200  ·  lpem.study@mcri.edu.au

Always discuss trial participation with your own doctor first.

Locations (1)

Murdoch Children's Research InstituteParkville, Victoria, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07359183